« Return to News | R&D Trends

Bayer, Ventana collaborate on test for personalized cancer therapy

Wednesday, January 18, 2012 12:05 PM

Bayer Pharma has collaborated with Ventana Medical Systems, a member of the Roche Group, to develop a molecular companion diagnostic test to identify patients most likely to benefit from a novel Bayer antibody-drug conjugate (ADC).

Ventana will initially develop, manufacture and commercialize a companion diagnostic test for one of Bayer’s ADCs. Both parties may initiate further development projects to develop molecular diagnostic tests over the next five years.

Bayer’s choice to partner with Ventana was based on the latter's diagnostic immunohistochemistry platform, which aims to analyze the expression level of certain tumor targets serving as biomarkers in clinical studies for patient selection. Ventana has also recently formed partnerships with Pfizer and Syndax Pharmaceuticals.

"We are very excited to partner with Ventana to develop a companion diagnostic for one of our ADC projects," said Andreas Busch, head of Global Drug Discovery for Bayer. "This constitutes another step for Bayer towards personalized medicine in cancer treatment as the selection of patients most likely to benefit from an ADC will increase the overall probability of therapeutic success for patients suffering from cancer."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.